Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises DGC in connection with EQT’s acquisition of shares in DGC and subsequent mandatory offer
Mandate

Vinge advises DGC in connection with EQT’s acquisition of shares in DGC and subsequent mandatory offer

June 07, 2017 Capital Markets and Public M&A

Vinge advises DGC One AB (publ) (“DGC”) in connection with EQT’s acquisition of 85.2 percent of the total number of shares and votes in DGC and subsequent mandatory recommended cash offer to the remaining shareholders.

EQT offers SEK 250 in cash per share in DGC. The total offer value for DGC amounts to approximately SEK 2.3 billion.

Vinge’s team consists of Göran Nyström, Dain Hård Nevonen and Sofie Bjärtun. Marcus Glader advices on competition law matters.

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026